Back to Search Start Over

Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies

Authors :
Agnieszka Tomaszewska
Madan Jagasia
Eric Beohou
Steffie van der Werf
Didier Blaise
Edward Kanfer
Noel Milpied
Péter Reményi
Fabio Ciceri
Jean H. Bourhis
Patrice Chevallier
Carlos Solano
Gerard Socié
Benedetto Bruno
Alessandro Rambaldi
Luca Castagna
Nicolaus Kröger
Paolo Corradini
Boris Afanasyev
Marco Ladetto
Dietger Niederwieser
Christof Scheid
Henrik Sengeloev
Frank Kroschinsky
Ibrahim Yakoub-Agha
Helene Schoemans
Christian Koenecke
Olaf Penack
Zinaida Perić
Hildegard Greinix
Rafael F. Duarte
Grzegorz W. Basak
Source :
Frontiers in Immunology, Vol 11 (2021)
Publication Year :
2021
Publisher :
Frontiers Media S.A., 2021.

Abstract

Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no randomized prospective data to validate this practice, although single center data and the CIBMTR analysis have shown promising results. We aimed at validation of these findings in a large registry study. We conducted a retrospective analysis using the EBMT registry of 3,803 adult patients with B-cell malignancies undergoing alloHCT (2001–2013) with either rituximab (R-RIC-9%) or non-rituximab (RIC-91%) reduced intensity regimens respectively. Median age and median follow up were 55 years (range 19.1–77.3) and 43.2 months (range 0.3–179.8), respectively. There was no difference in transplant outcomes (R-RIC vs RIC), including 1-year overall survival (69.9% vs 70.7%), 1-year disease-free survival (64.4% vs 62.2%), 1-year non-relapse mortality (21% vs 22%), and day-100 incidence of acute GVHD 2-4° (12% vs 12%). In summary, we found that addition of rituximab in RIC regimens for B-cell malignancies had no significant impact on major transplant outcome variables. Of note, data on chronic GVHD was not available, limiting the conclusions that can be drawn from the present study.

Details

Language :
English
ISSN :
16643224
Volume :
11
Database :
Directory of Open Access Journals
Journal :
Frontiers in Immunology
Publication Type :
Academic Journal
Accession number :
edsdoj.4f239d6d85d44aa8a589abee520c5fad
Document Type :
article
Full Text :
https://doi.org/10.3389/fimmu.2020.613954